Ashland Inc. Reports Q3 2026 Results: Growth in Sales, Strong Cash Flow, and Reaffirmed Guidance
Key Financial Highlights
- Sales: \$497 million, a 7% increase from the prior-year quarter.
- Net Income: \$16 million, or \$0.35 per diluted share.
- Income from Continuing Operations: \$41 million (\$0.89 per diluted share).
- Adjusted Income from Continuing Operations Excluding Intangibles Amortization: \$47 million (\$1.02 per diluted share).
- Adjusted EBITDA: \$109 million, down 4% year-over-year, reflecting mixed performance across business units.
- Sales Volumes: Up 6% year-over-year, with gains across all business units.
- Operating Cash Flows: \$121 million, up from \$114 million in the prior-year quarter, driven by working capital improvements.
- Ongoing Free Cash Flow: \$103 million (ongoing free cash flow conversion above 90%).
Full-Year 2026 Guidance Reaffirmed
- Sales Guidance: \$1,835–\$1,870 million.
- Adjusted EBITDA Guidance: \$385–\$400 million.
- Adjusted EPS Outlook: Revised to low-to-mid-single digit growth (down from mid-to-high-single digit growth) due to a higher tax rate associated with unfavorable discrete items.
- Ongoing Free Cash Flow Conversion: Expected to remain above 50% of Adjusted EBITDA with capex of ~\$90 million.
Segment Performance Analysis
- Life Sciences & Personal Care: Demonstrated growth and resilient demand, contributing positively to overall results.
- Specialty Additives and Intermediates: Segment earnings were lower, with Additives facing continued demand weakness and higher operating costs due to lower production rates experienced earlier in the fiscal year. Intermediates sales grew 12% year-over-year to \$37 million, including gains in merchant and captive butanediol (BDO) sales.
- Unallocated and Corporate Expense: Improved year-over-year due to lower environmental expenses and tax credits, though partially offset by higher compensation-related expenses.
Operational and Strategic Developments
- Improved Working Capital: Key driver of higher operating cash flow and ongoing free cash flow conversion.
- Foreign Currency Tailwinds: Provided a \$1 million boost to segment sales and Adjusted EBITDA.
- Innovation & High-Value Applications: Ongoing momentum in higher value, differentiated applications—especially in Life Sciences and Personal Care—remains a strategic focus.
- Portfolio Management: Continued deliberate actions in Construction and Energy & Resources segments to address softness in demand and optimize the portfolio.
- Pricing Actions: Recent price increases are being realized and are expected to support margin and earnings improvement.
Price-Sensitive Items and Shareholder Considerations
- Maintained Guidance: Despite a challenging macroeconomic environment, Ashland reaffirmed its full-year sales and Adjusted EBITDA guidance, signaling management’s confidence in the underlying business trends and operational improvements.
- EPS Outlook Revision: The adjusted EPS outlook was trimmed due to a higher-than-expected tax rate from discrete items. While this lowers the growth rate, the company still expects EPS growth.
- Segment Performance Differentiation: Life Sciences and Personal Care are driving growth, while Specialty Additives and Intermediates are still recovering from operational headwinds.
- Resilient Core Markets: Demand in core Life Sciences and Personal Care end markets remains stable and resilient, which is strategically important and could support share value.
- Commentary from Management: CEO Guillermo Novo highlighted continued sequential improvement expected into Q4 and fiscal 2027, ongoing innovation, and strong execution as key drivers for future value creation.
- Strong Cash Generation: High free cash flow conversion and disciplined capex support shareholder value and potential for capital return.
Risks and Forward-Looking Statements
- Macroeconomic Backdrop: Management cautioned on a mixed macro environment and ongoing inflationary pressures.
- Higher Tax Rate: EPS could be further pressured if additional unfavorable tax items emerge.
- Operational Risks: Risks remain around production rates, supply chain, and continued softness in Construction and Energy segments.
- Legal and Regulatory Risks: Ongoing exposure to environmental, health, and safety regulations, as well as pending and threatened asbestos-related litigation, could impact future results.
Upcoming Investor Events
Ashland will host a live webcast and Q&A for analysts at 9 a.m. ET on July 29, 2026. A supporting slide presentation will also be posted online and an archive of the webcast will be available for 12 months.
About Ashland Inc.
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company serving a wide range of consumer and industrial markets, including coatings, construction, energy, food and beverage, personal care, and pharmaceuticals. The company employs approximately 2,900 people worldwide.
Investor and Media Contact
- Sandy Klugman, Investor Relations: +1 (302) 594-7777, [email protected]
- Carolmarie C. Brown, Media Relations: +1 (302) 995-3158, [email protected]
Disclaimer: This article is for informational purposes only and does not constitute financial advice or an offer to buy or sell any securities. Investors should review Ashland’s official filings and consult with their own advisors before making investment decisions. Financial results are preliminary until Ashland’s Form 10-Q is filed with the U.S. Securities and Exchange Commission. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
